GSK, Merck vaccines keep kids out of hospital

GlaxoSmithKline's ($GSK) Rotarix and Merck's ($MRK) RotaTeq, vaccines designed to fight rotavirus, did their jobs, a Journal of the American Medical Association (JAMA) study found. The number of rotavirus-related hospitalizations in kids under 5 fell by 80% after the shots went into routine use, and the hospitalizations in kids 5-14 years dropped by 70%. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.